Keywords：方药研究, 实验研究, 配方资产, 转化沟通, 6.3 结论
Section Index
3.3 Effect of Pei’s Soft Liver and Anti-Bloating Pill on Immune Organs—Thymus and Spleen—in Tumor-Bearing Mice
After the administration of Pei’s Soft Liver and Anti-Bloating Pill, it is observed that the thymus and spleen in the model control group shrink in size and weight, with the thymus becoming grayish-white and poorly lobulated, and the spleen turning pale red. In the PRGXP large, medium, and small dose groups, the thymus index (TI) of the mice is higher than that of the model group, with the medium and large dose groups having TI values of (52.8±11.6) mg/10 g and (52.1±15.3) mg/10 g respectively, both of which are statistically significant compared with the model control group (P<0.05). The model group’s TI is lower than that of the blank control group (P<0.05). In the PRGXP dose groups, the spleen index (SI) of the mice is also higher than that of the model group, with the medium and large dose groups having SI values of (64.1±7.8) mg/10 g and (56.3±9.1) mg/10 g respectively, both of which are statistically significant compared with the model group (P<0.05). The model group’s SI is lower than that of the blank control group (P<0.05). There is no statistically significant difference between the PRGXP dose groups and the BM group (P>0.05). (See Table 2, Figure 3, and Figure 4)
Table 2: Effect of Pei’s Soft Liver and Anti-Bloating Pill on Thymus Index and Spleen Index in Tumor-Bearing Mice (x±s)
| Group | Dosage (g/kg) | Number of Mice | TI (mg/10 g) | SI (mg/10 g) |
|---|---|---|---|---|
| Blank Control Group | - | 12 | 60.6±10.8 | 70.6±13.0 |
| Model Control Group | - | 12 | 39.2±7.2 | 45.6±9.5 |
| PRGXP Small Dose Group | 1.0 | 12 | 44.6±10.7 | 56.2±9.2 |
| PRGXP Medium Dose Group | 2.0 | 12 | 52.8±11.6 | 64.1±7.8 |
| PRGXP Large Dose Group | 4.0 | 12 | 52.1±15.3 | 56.3±9.1 |
| BM Group | 0.25 | 12 | 51.3±15.8 | 61.6±11.1 |
Note: *P<0.05, compared with the model control group
This chapter is prepared for online research and reading; for external materials, please align with original publications and the review process.